异环磷酰胺联合表柔比星治疗骨肉瘤的疗效观察

Efficacy of Ifosfamide combined with epirubicin in the treatment of osteosarcoma

目的探讨异环磷酰胺联合表柔比星治疗骨肉瘤的临床疗效。方法选取2018年4月至2020年4月间靖边县人民医院收治的112例骨肉瘤患者(非转移性),采用随机数字表法分为观察组和对照组,每组56例。对照组患者采用异环磷酰胺治疗,观察组患者采用异环磷酰胺联合表柔比星治疗,比较两组患者治疗效果、生活质量、肢体功能评分、不良反应和治疗前后炎性因子水平。结果观察组患者生活质量和肢体功能评分均高于对照组,差异均有统计学意义(均P<0.05)。观察组患者治疗总有效率为94.6%,高于对照组的66.1%,差异有统计学意义(P<0.05)。观察组不良反应发生率为23.2%,低于对照组的62.5%,差异有统计学意义(P<0.05)。治疗后,观察组患者CRP、TNF-α和WBC均低于对照组,IL-10高于对照组,差异均有统计学意义(均P<0.05)。结论表柔比星联合异环磷酰胺治疗骨肉瘤,安全性高,不良反应少,可降低体内炎性因子水平,提高治疗效果,改善患者肢体功能和预后生活质量。

Objective To investigate the efficacy of ifosfamide combined with epirubicin in the treatment of osteosarcoma.Methods One hundred and twelve patients with osteosarcoma(non-metastatic)treated at Jingbian County People’s Hospital from April 2018 to April 2020 were selected.They were divided into an observation group and a control group using random number table with 56 patients in each group.The observation group was treated with ifosfamide plus epirubic and the control group was treated with ifosfamide.Treatment efficacy,quality of life,limb function,adverse reactions and inflammatory factor levels were compared between the two groups before and after the treatment.Results The quality of life and limb function scores were higher in the observation group than in the control group(all P<0.05).The overall efficacy rate was 94.6%in the observation group which was higher than 66.1%of the control group(P<0.05).The incidence of adverse reactions was 23.2%in the observation group lower than 62.5%of the control group(P<0.05).After the treatment,C-reactive protein(CRP),tumor necrosis factor(TNF)-αand white blood cell(WBC)levels were lower in the observation group than in the control group(all P<0.05).Conclusion Epirubicin combined with ifosfamide osteosarcoma shows high safety for osteosarcoma with few adverse reactions.It can reduce the level of inflammatory factors,improve the treatment efficacy limb function and prognosis and quality of life.